30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Nuvation Bio Inc (NUVB)

Track

Over the last 90 days, Nuvation Bio Inc. has seen a net insider buy of $118,250, with one insider transaction recorded. Notably, there was a single buy transaction of $118,250. The company's stock has experienced a 36.7% increase in the last 90 days. The last earnings report showed a significant beat of 188.43%.
Stock chart
Ticker: NUVB Exchange: NYS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Markel Stacy
CHIEF PEOPLE OFFICER
1 sale — total 100,000 USD
Planned sale 23 Jun 2026
Value US$1,632,455.96 | Price 232.62 | Shares 97,824
Planned sale 23 Jun 2026
Value US$3,489,843.67 | Price 331.13 | Shares 59,052
Planned sale 23 Jun 2026
Value US$100,000.00 | Price 6.01 | Shares 1,000
Proposed sale 23 Jun 2026
Value US$100,000.00 | Price 5.76 | Shares 1,000
Proposed sale 23 Jun 2026
Value US$100,000.00 | Price 5.76 | Shares 1,000
Proposed sale 23 Jun 2026
Value US$100,000.00 | Price 5.76 | Shares 1,000
Buy 9 Jun 2026
Value US$100,000.00 | Price 4.73 | Shares 1,000
Planned sale 17 Apr 2026
Value US$184,279.20 | Price 5.01 | Shares 36,750
Planned sale 17 Apr 2026
Value US$251,000.00 | Price 5.02 | Shares 50,000
Proposed sale 17 Apr 2026
Value US$240,500.00 | Price 4.81 | Shares 50,000
Proposed sale 17 Apr 2026
Value US$176,767.50 | Price 4.81 | Shares 36,750
Planned sale 6 Apr 2026
Value US$903,560.00 | Price 4.52 | Shares 200,000
Proposed sale 6 Apr 2026
Value US$882,000.00 | Price 4.41 | Shares 200,000
Sale 1 Dec 2025
Value US$1,173,255.00 | Price 7.82 | Shares 150,000
Proposed sale 1 Dec 2025
Value US$1,173,255.00 | Price 7.82 | Shares 150,000
Proposed sale 26 Nov 2025
Value US$80,000.00 | Price 8.00 | Shares 10,000
Sale 26 Nov 2025
Value US$80,000.00 | Price 8.00 | Shares 10,000
Sale 25 Nov 2025
Value US$75,000.00 | Price 7.50 | Shares 10,000
Proposed sale 25 Nov 2025
Value US$75,000.00 | Price 7.50 | Shares 10,000
Sale 20 Nov 2025
Value US$140,074.00 | Price 7.00 | Shares 20,000
Sale 20 Nov 2025
Value US$2,168,100.00 | Price 7.23 | Shares 300,000
Sale 20 Nov 2025
Value US$499,031.58 | Price 7.23 | Shares 69,051
Proposed sale 20 Nov 2025
Value US$2,667,131.58 | Price 7.23 | Shares 369,051
Proposed sale 20 Nov 2025
Value US$140,074.00 | Price 7.00 | Shares 20,000
Sale 19 Nov 2025
Value US$1,427,680.00 | Price 7.14 | Shares 200,000
Proposed sale 19 Nov 2025
Value US$76,552.50 | Price 5.10 | Shares 15,000
Proposed sale 19 Nov 2025
Value US$1,427,680.00 | Price 7.14 | Shares 200,000
Planned sale 19 Nov 2025
Value US$76,552.50 | Price 5.10 | Shares 15,000
Sale 17 Nov 2025
Value US$71,475.00 | Price 4.77 | Shares 15,000
Proposed sale 17 Nov 2025
Value US$71,475.00 | Price 4.77 | Shares 15,000
Planned sale 27 Oct 2025
Value US$502,460.00 | Price 5.02 | Shares 100,000
Proposed sale 27 Oct 2025
Value US$485,000.00 | Price 4.85 | Shares 100,000
Planned buy 18 Jun 2025
Value US$17,100.00 | Price 1.71 | Shares 10,000
Buy 17 Jun 2025
Value US$7,160.00 | Price 1.79 | Shares 4,000
Buy 16 Jun 2025
Value US$43,200.00 | Price 1.80 | Shares 24,000
Buy 16 Jun 2025
Value US$46,540.00 | Price 1.79 | Shares 26,000
Planned buy 16 Jun 2025
Value US$90,350.00 | Price 1.81 | Shares 50,000
Planned buy 16 Jun 2025
Value US$6,055.50 | Price 1.84 | Shares 3,300
Buy 16 Jun 2025
Value US$893,500.00 | Price 1.79 | Shares 500,000
Planned sale 2 May 2025
Value US$50,024.00 | Price 2.50 | Shares 20,000
Proposed sale 2 May 2025
Value US$45,400.00 | Price 2.27 | Shares 20,000
Buy 7 Apr 2025
Value US$487,500.00 | Price 1.63 | Shares 300,000
Buy 4 Apr 2025
Value US$332,720.00 | Price 1.66 | Shares 200,000
Buy 1 Apr 2025
Value US$165,153.11 | Price 1.67 | Shares 98,900
Buy 1 Apr 2025
Value US$1,832.05 | Price 1.67 | Shares 1,100
Sale 11 Nov 2024
Value US$162,883.29 | Price 2.89 | Shares 56,361
Buy 8 Oct 2024
Value US$219,958.20 | Price 2.20 | Shares 99,981
Buy 8 Oct 2024
Value US$41.70 | Price 2.20 | Shares 19
Buy 25 Jun 2024
Value US$825,348.15 | Price 2.97 | Shares 277,895
Buy 24 Jun 2024
Value US$1,003,884.52 | Price 2.98 | Shares 336,874
Buy 21 Jun 2024
Value US$226,233.00 | Price 3.00 | Shares 75,411
Buy 20 Jun 2024
Value US$262,267.85 | Price 2.99 | Shares 87,715
Buy 11 Jun 2024
Value US$500,088.51 | Price 2.90 | Shares 172,189
Buy 21 Feb 2023
Value US$72,138.30 | Price 1.36 | Shares 53,000
Buy 20 Feb 2023
Value US$159,490.20 | Price 1.36 | Shares 117,100
Buy 19 Feb 2023
Value US$6,460,636.60 | Price 1.26 | Shares 5,143,000
Buy 5 Dec 2022
Value US$83,961.80 | Price 1.95 | Shares 43,000
Buy 2 Dec 2022
Value US$93,186.90 | Price 1.98 | Shares 47,000
Buy 1 Dec 2022
Value US$167,598.62 | Price 1.97 | Shares 84,959
Buy 30 Nov 2022
Value US$139,088.49 | Price 1.85 | Shares 75,041
Sale 5 Apr 2022
Value US$14,000,000.00 | Price 5.60 | Shares 2,500,000
Sale 15 Dec 2021
Value US$5,035,000.00 | Price 10.07 | Shares 500,000
Sale 7 Dec 2021
Value US$13,720,000.00 | Price 9.80 | Shares 1,400,000
Buy 24 Nov 2021
Value US$167,229.81 | Price 7.69 | Shares 21,758
Buy 24 Nov 2021
Value US$1,254,861.52 | Price 7.69 | Shares 163,268
Sale 23 Nov 2021
Value US$351.00 | Price 9.75 | Shares 36
Sale 22 Nov 2021
Value US$2,879,200.00 | Price 9.76 | Shares 295,000
Sale 3 Nov 2021
Value US$18,500,000.00 | Price 9.25 | Shares 2,000,000
Sale 29 Oct 2021
Value US$417,150.00 | Price 9.27 | Shares 45,000
Sale 28 Oct 2021
Value US$9,744,000.00 | Price 9.60 | Shares 1,015,000
Sale 31 Jul 2021
Value US$489,006.72 | Price 8.64 | Shares 56,598
Buy 31 Jul 2021
Value US$489,006.72 | Price 8.64 | Shares 56,598
Buy 31 Mar 2021
Value US$1,583,634.80 | Price 10.45 | Shares 151,544
Buy 30 Mar 2021
Value US$49,899.50 | Price 9.98 | Shares 5,000
Buy 6 Jul 2020
Value US$3,900,000.00 | Price 10.00 | Shares 390,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-24 2026-06-23 PlS Planned sale
Markel Stacy

CHIEF PEOPLE OFFICER

Officer
97,824 +39.4%
232.62
US$1,632,456 		97,824 +39.4% 232.62 US$1,632,456
2026-06-24 2026-06-23 PlS Planned sale
3.4
Wentworth Kerry

CHIEF REGULATORY OFFICER

Officer
59,052 -37.3%
331.13
US$3,489,844 		59,052 -37.3% 331.13 US$3,489,844
2026-06-24 2026-06-23 PlS Planned sale
3.4
Sauvage Philippe

Chief Financial Officer

Officer
71,936 +8.6%
390.21
US$3,453,006 		71,936 +8.6% 390.21 US$3,453,006
2026-06-23 2026-06-23 PrS Proposed sale
3.4
KERRY WENTWORTH

Officer

Officer
1,000
5.76
US$100,000 		1,000 5.76 US$100,000
2026-06-23 2026-06-23 PrS Proposed sale
PHILIPPE SAUVAGE

Officer

Officer
1,000
5.76
US$100,000 		1,000 5.76 US$100,000
2026-06-23 2026-06-23 PrS Proposed sale
STACY MARKEL

Officer

Officer
1,000
5.76
US$100,000 		1,000 5.76 US$100,000
2026-06-11 2026-06-09 B Purchase
3.7
Mashal Robert
Non-Executive Director
1,000 +12.5%
4.73
US$100,000 		1,000 +12.5% 4.73 US$100,000
2026-04-21 2026-04-17 PlS Planned sale
3.4
Wentworth Kerry

CHIEF REGULATORY OFFICER

Officer
36,750 -40.9%
5.01
US$184,279 		36,750 -40.9% 5.01 US$184,279
2026-04-21 2026-04-17 PlS Planned sale
2.6
Liu Dongfang

CHIEF MEDICAL OFFICER

Officer
50,000 -73.5%
5.02
US$251,000 		50,000 -73.5% 5.02 US$251,000
2026-04-17 2026-04-17 PrS Proposed sale
2.6
DONGFANG LIU

Officer

Officer
50,000
4.81
US$240,500 		50,000 4.81 US$240,500
2026-04-17 2026-04-17 PrS Proposed sale
3.4
KERRY WENTWORTH

Officer

Officer
36,750
4.81
US$176,768 		36,750 4.81 US$176,768
2026-04-08 2026-04-06 PlS Planned sale
3.4
Wentworth Kerry

CHIEF REGULATORY OFFICER

Officer
200,000 -79.1%
4.52
US$903,560 		200,000 -79.1% 4.52 US$903,560
2026-04-06 2026-04-06 PrS Proposed sale
3.4
KERRY WENTWORTH

Officer

Officer
200,000
4.41
US$882,000 		200,000 4.41 US$882,000
2025-12-03 2025-12-01 S Sale
2.6
Liu Dongfang

CHIEF MEDICAL OFFICER

Officer
150,000 -89.3%
7.82
US$1,173,255 		150,000 -89.3% 7.82 US$1,173,255
2025-12-01 2025-12-01 PrS Proposed sale
2.6
DONGFANG LIU

Officer

Officer
150,000
7.82
US$1,173,255 		150,000 7.82 US$1,173,255
2025-11-26 2025-11-26 PrS Proposed sale
2.6
DONGFANG LIU

Officer

Officer
10,000
8.00
US$80,000 		10,000 8.00 US$80,000
2025-11-26 2025-11-26 S Sale
2.6
Liu Dongfang

CHIEF MEDICAL OFFICER

Officer
10,000 -35.7%
8.00
US$80,000 		10,000 -35.7% 8.00 US$80,000
2025-11-26 2025-11-25 S Sale
2.6
Liu Dongfang

CHIEF MEDICAL OFFICER

Officer
10,000 -35.7%
7.50
US$75,000 		10,000 -35.7% 7.50 US$75,000
2025-11-25 2025-11-25 PrS Proposed sale
2.6
DONGFANG LIU

Officer

Officer
10,000
7.50
US$75,000 		10,000 7.50 US$75,000
2025-11-24 2025-11-20 S Sale
2.6
Liu Dongfang

CHIEF MEDICAL OFFICER

Officer
20,000 -52.6%
7.00
US$140,074 		20,000 -52.6% 7.00 US$140,074
2025-11-24 2025-11-20 S Sale
2.3
Hattersley Gary

CHIEF SCIENTIFIC OFFICER

Officer
300,000 -100.0%
7.23
US$2,168,100 		300,000 -100.0% 7.23 US$2,168,100
2025-11-24 2025-11-20 S Sale
2.3
Hattersley Gary

CHIEF SCIENTIFIC OFFICER

Officer
69,051 -100.0%
7.23
US$499,032 		69,051 -100.0% 7.23 US$499,032
2025-11-20 2025-11-20 PrS Proposed sale
2.3
GARY HATTERSLEY

Officer

Officer
369,051
7.23
US$2,667,132 		369,051 7.23 US$2,667,132
2025-11-20 2025-11-20 PrS Proposed sale
2.6
DONGFANG LIU

Officer

Officer
20,000
7.00
US$140,074 		20,000 7.00 US$140,074
2025-11-21 2025-11-19 S Sale
2.3
Hanley David C.

CHIEF TECHNICAL OPERATIONS

Officer
200,000 -89.3%
7.14
US$1,427,680 		200,000 -89.3% 7.14 US$1,427,680
2025-11-19 2025-11-19 PrS Proposed sale
2.6
DONGFANG LIU

Officer

Officer
15,000
5.10
US$76,552 		15,000 5.10 US$76,552
2025-11-19 2025-11-19 PrS Proposed sale
2.3
DAVID HANLEY

Officer

Officer
200,000
7.14
US$1,427,680 		200,000 7.14 US$1,427,680
2025-11-19 2025-11-19 PlS Planned sale
2.6
Liu Dongfang

CHIEF MEDICAL OFFICER

Officer
15,000 -45.5%
5.10
US$76,552 		15,000 -45.5% 5.10 US$76,552
2025-11-19 2025-11-17 S Sale
2.6
Liu Dongfang

CHIEF MEDICAL OFFICER

Officer
15,000 -50.0%
4.77
US$71,475 		15,000 -50.0% 4.77 US$71,475
2025-11-17 2025-11-17 PrS Proposed sale
2.6
DONGFANG LIU

Officer

Officer
15,000
4.77
US$71,475 		15,000 4.77 US$71,475
2025-10-29 2025-10-27 PlS Planned sale
2.3
Hattersley Gary

CHIEF SCIENTIFIC OFFICER

Officer
100,000 -100.0%
5.02
US$502,460 		100,000 -100.0% 5.02 US$502,460
2025-10-27 2025-10-27 PrS Proposed sale
2.3
GARY HATTERSLEY

Officer

Officer
100,000
4.85
US$485,000 		100,000 4.85 US$485,000
2025-06-18 2025-06-18 PP Planned purchase
Markel Stacy

CHIEF PEOPLE OFFICER

Officer
10,000 +51.0%
1.71
US$17,100 		10,000 +51.0% 1.71 US$17,100
2025-06-18 2025-06-17 B Purchase
3.4
Sauvage Philippe

Chief Financial Officer

Officer
4,000 +67.8%
1.79
US$7,160 		4,000 +67.8% 1.79 US$7,160
2025-06-18 2025-06-16 B Purchase
3.4
Wentworth Kerry

CHIEF REGULATORY OFFICER

Officer
24,000 +92.3%
1.80
US$43,200 		24,000 +92.3% 1.80 US$43,200
2025-06-18 2025-06-16 B Purchase
3.4
Wentworth Kerry

CHIEF REGULATORY OFFICER

Officer
26,000 +inf%
1.79
US$46,540 		26,000 +inf% 1.79 US$46,540
2025-06-18 2025-06-16 PP Planned purchase
Sjogren Colleen

Chief Commercial Officer

Officer
50,000 +161.3%
1.81
US$90,350 		50,000 +161.3% 1.81 US$90,350
2025-06-18 2025-06-16 PP Planned purchase
3.4
Sauvage Philippe

Chief Financial Officer

Officer
3,300 +126.8%
1.84
US$6,056 		3,300 +126.8% 1.84 US$6,056
2025-06-18 2025-06-16 B Purchase
3.6
Hung David

PRESIDENT AND CEO

Executive Director Large shareholder
500,000 +0.9%
1.79
US$893,500 		500,000 +0.9% 1.79 US$893,500
2025-05-06 2025-05-02 PlS Planned sale
2.6
Liu Dongfang

CHIEF MEDICAL OFFICER

Officer
20,000 -62.5%
2.50
US$50,024 		20,000 -62.5% 2.50 US$50,024
2025-05-02 2025-05-02 PrS Proposed sale
2.6
DONGFANG LIU

Officer

Officer
20,000
2.27
US$45,400 		20,000 2.27 US$45,400
2025-04-08 2025-04-07 B Purchase
3.6
Hung David

PRESIDENT AND CEO

Executive Director Large shareholder
300,000 +0.5%
1.63
US$487,500 		300,000 +0.5% 1.63 US$487,500
2025-04-08 2025-04-04 B Purchase
3.6
Hung David

PRESIDENT AND CEO

Executive Director Large shareholder
200,000 +0.3%
1.66
US$332,720 		200,000 +0.3% 1.66 US$332,720
2025-04-03 2025-04-01 B Purchase
3.7
Mashal Robert
Non-Executive Director
98,900 +97.8%
1.67
US$165,153 		98,900 +97.8% 1.67 US$165,153
2025-04-03 2025-04-01 B Purchase
3.7
Mashal Robert
Non-Executive Director
1,100 +1.1%
1.67
US$1,832 		1,100 +1.1% 1.67 US$1,832
2024-11-13 2024-11-11 S Sale
3.1
Wang Junyuan Jerry

CEO, ANHEART THERAPEUTICS LTD.

Executive Director
56,361 -1.4%
2.89
US$162,883 		56,361 -1.4% 2.89 US$162,883
2024-10-10 2024-10-08 B Purchase
3.7
Mashal Robert
Non-Executive Director
99,981 +526215.8%
2.20
US$219,958 		99,981 +526215.8% 2.20 US$219,958
2024-10-10 2024-10-08 B Purchase
3.7
Mashal Robert
Non-Executive Director
19 +inf%
2.20
US$42 		19 +inf% 2.20 US$42
2024-06-26 2024-06-25 B Purchase
3.7
Cui Xiangmin
Non-Executive Director
277,895 +12.8%
2.97
US$825,348 		277,895 +12.8% 2.97 US$825,348
2024-06-25 2024-06-24 B Purchase
3.7
Cui Xiangmin
Non-Executive Director
336,874 +18.3%
2.98
US$1,003,885 		336,874 +18.3% 2.98 US$1,003,885
2024-06-25 2024-06-21 B Purchase
3.7
Cui Xiangmin
Non-Executive Director
75,411 +4.3%
3.00
US$226,233 		75,411 +4.3% 3.00 US$226,233
2024-06-25 2024-06-20 B Purchase
3.7
Cui Xiangmin
Non-Executive Director
87,715 +5.2%
2.99
US$262,268 		87,715 +5.2% 2.99 US$262,268
2024-06-13 2024-06-11 B Purchase
3.1
BLICKENSTAFF KIM D
Non-Executive Director
172,189 +inf%
2.90
US$500,089 		172,189 +inf% 2.90 US$500,089
2023-09-21 2023-02-21 B Purchase
3.7
NODELMAN OLEG
Non-Executive Director
53,000 +0.4%
1.36
US$72,138 		53,000 +0.4% 1.36 US$72,138
2023-09-21 2023-02-20 B Purchase
3.7
NODELMAN OLEG
Non-Executive Director
117,100 +0.9%
1.36
US$159,490 		117,100 +0.9% 1.36 US$159,490
2023-09-21 2023-02-19 B Purchase
3.7
NODELMAN OLEG
Non-Executive Director
5,143,000 +69.9%
1.26
US$6,460,637 		5,143,000 +69.9% 1.26 US$6,460,637
2022-12-05 2022-12-05 B Purchase
3.1
FALBERG KATHRYN E
Non-Executive Director
43,000 +20.8%
1.95
US$83,962 		43,000 +20.8% 1.95 US$83,962
2022-12-05 2022-12-02 B Purchase
3.1
FALBERG KATHRYN E
Non-Executive Director
47,000 +29.4%
1.98
US$93,187 		47,000 +29.4% 1.98 US$93,187
2022-12-05 2022-12-01 B Purchase
3.1
FALBERG KATHRYN E
Non-Executive Director
84,959 +113.2%
1.97
US$167,599 		84,959 +113.2% 1.97 US$167,599
2022-12-05 2022-11-30 B Purchase
3.1
FALBERG KATHRYN E
Non-Executive Director
75,041 +inf%
1.85
US$139,088 		75,041 +inf% 1.85 US$139,088
2022-04-07 2022-04-05 S Sale
4.2
Omega Fund V, L.P.
Large shareholder
2,500,000 -10.9%
5.60
US$14,000,000 		2,500,000 -10.9% 5.60 US$14,000,000
2021-12-17 2021-12-15 S Sale
4.2
Omega Fund V, L.P.
Large shareholder
500,000 -2.1%
10.07
US$5,035,000 		500,000 -2.1% 10.07 US$5,035,000
2021-12-09 2021-12-07 S Sale
4.2
Omega Fund V, L.P.
Large shareholder
1,400,000 -5.6%
9.80
US$13,720,000 		1,400,000 -5.6% 9.80 US$13,720,000
2021-11-30 2021-11-24 B Purchase
3.7
NODELMAN OLEG
Non-Executive Director
21,758 +1.9%
7.69
US$167,230 		21,758 +1.9% 7.69 US$167,230
2021-11-30 2021-11-24 B Purchase
3.7
NODELMAN OLEG
Non-Executive Director
163,268 +2.3%
7.69
US$1,254,862 		163,268 +2.3% 7.69 US$1,254,862
2021-11-24 2021-11-23 S Sale
4.2
Omega Fund V, L.P.
Large shareholder
36 -0.0%
9.75
US$351 		36 -0.0% 9.75 US$351
2021-11-24 2021-11-22 S Sale
4.2
Omega Fund V, L.P.
Large shareholder
295,000 -1.2%
9.76
US$2,879,200 		295,000 -1.2% 9.76 US$2,879,200
2021-11-05 2021-11-03 S Sale
4.2
Omega Fund V, L.P.
Large shareholder
2,000,000 -7.4%
9.25
US$18,500,000 		2,000,000 -7.4% 9.25 US$18,500,000
2021-11-01 2021-10-29 S Sale
4.2
Omega Fund V, L.P.
Large shareholder
45,000 -0.2%
9.27
US$417,150 		45,000 -0.2% 9.27 US$417,150
2021-11-01 2021-10-28 S Sale
4.2
Omega Fund V, L.P.
Large shareholder
1,015,000 -3.6%
9.60
US$9,744,000 		1,015,000 -3.6% 9.60 US$9,744,000
2021-11-30 2021-07-31 S Sale
3.7
NODELMAN OLEG
Non-Executive Director
56,598 -4.7%
8.64
US$489,007 		56,598 -4.7% 8.64 US$489,007
2021-11-30 2021-07-31 B Purchase
3.7
NODELMAN OLEG
Non-Executive Director
56,598 +0.8%
8.64
US$489,007 		56,598 +0.8% 8.64 US$489,007
2021-11-30 2021-03-31 B Purchase
3.7
NODELMAN OLEG
Non-Executive Director
151,544 +2.3%
10.45
US$1,583,635 		151,544 +2.3% 10.45 US$1,583,635
2021-04-01 2021-03-30 B Purchase
3.6
Bazemore Robert B
Non-Executive Director
5,000 +inf%
9.98
US$49,900 		5,000 +inf% 9.98 US$49,900
2020-07-06 2020-07-06 B Purchase
2.6
EcoR1 Panacea Holdings, LLC
Non-Executive Director Large shareholder
390,000 +inf%
10.00
US$3,900,000 		390,000 +inf% 10.00 US$3,900,000
Explore more

More insider trading research around Nuvation Bio Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America